GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...
ESMO: GSK's Zejula misses survival goal in first-line ovarian cancer, as pharma&'s combo disappoints
In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...
GSK Plc’s experimental drug helped prevent serious asthma attacks in two late-stage studies, easing the path forward for a medicine that the British company says could reach £3 billion ($3.9 billion) ...
GSK's oncology R&D head. Abdullah joined GSK in 2019, after eight years at the oncology business of U.K. rival AstraZeneca, where he was vice president and global head of immuno-oncology.
GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the ...
GSK-3739937 is commercialized by GSK, with a leading Phase I program in Human Immunodeficiency Virus (HIV) Infections (AIDS).
Rise and shine, everyone, another busy day is on the way. However, this is also shaping up as a beautiful day as well, despite forecasts predicting rising ...
5d
Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...
GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it ...
China's health authority has granted GSK's Blenrep blood cancer treatment with a so-called 'Breakthrough Therapy Designation' ...
GlobalData uses proprietary data and analytics to provide a complete picture of GSK -3943104A’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here. The revenue for GSK -3943104A is ...
Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback